Literature DB >> 9932262

How to perforate safely a resistant floor of the 3rd ventricle? Technical note.

U Kehler1, J Gliemroth, U Knopp, H Arnold.   

Abstract

Third ventriculostomy for acquired non-communicating hydrocephalus is an excellent alternative to shunting procedures. Nevertheless, complications can be severe and even fatal (e.g., lesion of the basilar artery), especially if the floor of the 3rd ventricle is very tough and/or opaque. The authors describe a safe method of sharp perforation of the floor, which should be applied if blunt fenestration cannot be achieved easily.

Entities:  

Mesh:

Year:  1998        PMID: 9932262     DOI: 10.1055/s-2008-1052041

Source DB:  PubMed          Journal:  Minim Invasive Neurosurg        ISSN: 0946-7211


  5 in total

Review 1.  Long-term complications and definition of failure of neuroendoscopic procedures.

Authors:  Tjemme Beems; J Andre Grotenhuis
Journal:  Childs Nerv Syst       Date:  2004-06-10       Impact factor: 1.475

Review 2.  Shunts vs endoscopic third ventriculostomy in infants: are there different types and/or rates of complications? A review.

Authors:  C Di Rocco; L Massimi; G Tamburrini
Journal:  Childs Nerv Syst       Date:  2006-10-20       Impact factor: 1.475

Review 3.  Endoscopic third ventriculostomy for obstructive hydrocephalus.

Authors:  Dieter Hellwig; Joachim Andreas Grotenhuis; Wuttipong Tirakotai; Thomas Riegel; Dirk Michael Schulte; Bernhard Ludwig Bauer; Helmut Bertalanffy
Journal:  Neurosurg Rev       Date:  2004-11-27       Impact factor: 3.042

4.  Endoscopic third ventriculostomy - effectiveness of the procedure for obstructive hydrocephalus with different etiology in adults.

Authors:  Krzysztof Stachura; Ewelina Grzywna; Borys M Kwinta; Marek M Moskała
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-10-16       Impact factor: 1.195

5.  First experiences with a 2.0-microm near infrared laser system for neuroendoscopy.

Authors:  H C Ludwig; T Kruschat; T Knobloch; H-O Teichmann; K Rostasy; V Rohde
Journal:  Neurosurg Rev       Date:  2007-05-04       Impact factor: 2.800

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.